The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Positive data from clinical trial

nancy591
nancy591 CSN Member Posts: 1,027 Member
edited March 2014 in Ovarian Cancer #1
I found this article at ovariancancer.org. Thought everyone may be interested:

Nektar has positive data from ovarian cancer study
Nektar Therapeutics on Monday reported that early results from a trial of an experimental cancer drug suggest a slowing in the progression of ovarian cancer.

The results come from a mid-stage study of a drug candidate called NKTR-102. The company is testing the drug on women whose cancer has progressed despite treatment with platinum-based chemotherapy.

Nektar said women who took the drug every three weeks had a median survival of 21 weeks before their cancer began to progress again or the died. Women who took the drug once every two weeks had median survival of 12.2 weeks.

The company said currently approved drugs halt the progression of ovarian cancer for 9.1 weeks to 13.6 weeks.

Nektar said the results come from 39 women in the study. A total of 71 patients are involved in the study and full results are expected later this year. The company is also testing NKTR-102 as a treatment for cancers of the breast, colon, and cervix.


Read the full article at: ovariancancer.org
Like Care

Comments

Discussion Boards